Abstract
Objective:
To evaluate a new antibiotic strategy with a combination of ofloxacin + co-amoxiclav in the treatment of pelvic infectious diseases.
Design:
An open-non-comparative multicentre (10) study.
Subjects:
123 patients (118 salpingitis and 5 endometritis) were included clinical, laparoscopic and bacteriological assessments were performed before treatment and a laparoscopic control was done in 35% of cases. Among positive bacteriological samples before treatment 48.7% C. trachomatis were isolated; 56.1% of salpingitis were considered as severe (COGIT score > 6).
Treatment:
Patients received at entry oral ofloxacin 200 mg bid in combination with parenteral co-amoxiclav 2 to 4 g following by oral route. Total duration of treatment was 21 days.
Results:
With respectively 97.2% and 91.6% satisfactory clinical and bacteriological results, this combination should take a major place in the treatment of pelvic infectious diseases.
Publication types
-
Clinical Trial
-
English Abstract
-
Multicenter Study
MeSH terms
-
Adolescent
-
Adult
-
Amoxicillin / administration & dosage
-
Amoxicillin / therapeutic use*
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / therapeutic use*
-
Bacterial Infections / drug therapy*
-
Chlamydia Infections / drug therapy
-
Chlamydia trachomatis
-
Clavulanic Acid
-
Clavulanic Acids / administration & dosage
-
Clavulanic Acids / therapeutic use*
-
Drug Therapy, Combination / therapeutic use*
-
Drug Tolerance
-
Endometritis / drug therapy
-
Endometritis / microbiology
-
Female
-
Follow-Up Studies
-
Genital Diseases, Female / drug therapy*
-
Genital Diseases, Female / microbiology*
-
Humans
-
Middle Aged
-
Ofloxacin / administration & dosage
-
Ofloxacin / therapeutic use*
-
Pelvic Inflammatory Disease / drug therapy
-
Pelvic Inflammatory Disease / microbiology
-
Remission Induction
-
Salpingitis / drug therapy
-
Salpingitis / microbiology
-
beta-Lactamase Inhibitors*
-
beta-Lactamases / administration & dosage
-
beta-Lactamases / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Clavulanic Acids
-
beta-Lactamase Inhibitors
-
Clavulanic Acid
-
Amoxicillin
-
Ofloxacin
-
beta-Lactamases